BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rose DN. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. Ann Intern Med. 1998;129:779-786. [PMID: 9841583 DOI: 10.7326/0003-4819-129-10-199811150-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Steffen RE, Pinto M, Kritski A, Trajman A. Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV. Sci Rep 2020;10:21823. [PMID: 33311520 DOI: 10.1038/s41598-020-78737-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virology 2015; 4(2): 105-112 [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
3 Diel R, Lampenius N, Nienhaus A. Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations. PharmacoEconomics 2015;33:783-809. [DOI: 10.1007/s40273-015-0267-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
4 Foglia E, Bonfanti P, Rizzardini G, Bonizzoni E, Restelli U, Ricci E, Porazzi E, Scolari F, Croce D. Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world. PLoS One 2013;8:e57777. [PMID: 23460905 DOI: 10.1371/journal.pone.0057777] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
5 Maheswaran H, Barton P. Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis. PLoS One 2012;7:e30457. [PMID: 22291958 DOI: 10.1371/journal.pone.0030457] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
6 Santín Cerezales M, Navas Elorza E. Tuberculosis in special populations. Enferm Infecc Microbiol Clin 2011;29 Suppl 1:20-5. [PMID: 21420563 DOI: 10.1016/S0213-005X(11)70014-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
7 Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update: Treatment of latent TB infection. Respirology 2010;15:603-22. [DOI: 10.1111/j.1440-1843.2010.01751.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 139] [Article Influence: 11.2] [Reference Citation Analysis]
8 Tillekeratne LG, Thielman NM, Kiwera RA, Chu HY, Kaale L, Morpeth SC, Ostermann J, Mtweve SP, Shao JF, Bartlett JA, Crump JA. Morbidity and mortality among a cohort of HIV-infected adults in a programme for community home-based care, in the Kilimanjaro Region of Tanzania (2003-2005). Ann Trop Med Parasitol 2009;103:263-73. [PMID: 19341540 DOI: 10.1179/136485909X398203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
9 Sánchez F, Balagué M, García de Olalla P, López Colomés JL, Martín V, Guerrero R, Marco A, Caylà JA. Treatment of latent Mycobacterium tuberculosis infection in intravenous drug users co-infected with HIV. Journal of Infection Prevention 2010;11:12-8. [DOI: 10.1177/1757177409354732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Tan MC, Marra CA, Sadatsafavi M, Marra F, Morán-Mendoza O, Moadebi S, Elwood RK, FitzGerald JM. Cost-effectiveness of LTBI treatment for TB contacts in British Columbia. Value Health 2008;11:842-52. [PMID: 18489519 DOI: 10.1111/j.1524-4733.2008.00334.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
11 Uebel KE, Nash J, Avalos A. Caring for the caregivers: models of HIV/AIDS care and treatment provision for health care workers in Southern Africa. J Infect Dis 2007;196 Suppl 3:S500-4. [PMID: 18181701 DOI: 10.1086/521113] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
12 Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 2007;196 Suppl 1:S52-62. [PMID: 17624827 DOI: 10.1086/518662] [Cited by in Crossref: 46] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
13 Hornberger J, Holodniy M, Robertus K, Winnike M, Gibson E, Verhulst E. A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy. Med Decis Making 2007;27:789-821. [DOI: 10.1177/0272989x07306112] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
14 Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, Gourgiotis D, Tsolia MN. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22. [PMID: 17712755 DOI: 10.1086/520983] [Cited by in Crossref: 158] [Cited by in F6Publishing: 165] [Article Influence: 10.5] [Reference Citation Analysis]
15 Hamlyn E, Childs K, Post FA. Reducing Tuberculosis Incidence in HIV-Infected Patients by Tuberculin Skin Testing, Preventive Treatment, and Antiretroviral Therapy. Clinical Infectious Diseases 2007;44:1393-4. [DOI: 10.1086/516608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
16 Armbruster B, Brandeau ML. Optimal mix of screening and contact tracing for endemic diseases. Math Biosci 2007;209:386-402. [PMID: 17428503 DOI: 10.1016/j.mbs.2007.02.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
17 Tripathi RP, Tewari N, Dwivedi N, Tiwari VK. Fighting tuberculosis: An old disease with new challenges. Med Res Rev 2005;25:93-131. [DOI: 10.1002/med.20017] [Cited by in Crossref: 152] [Cited by in F6Publishing: 156] [Article Influence: 8.9] [Reference Citation Analysis]
18 Lacombe K, Girard PM. [Treatment and prophylaxis of opportunistic infections in the course of HIV disease: a state of the art in 2004. Part 2: Viral, fungal and bacterial infections]. Med Mal Infect 2004;34:246-56. [PMID: 15612357 DOI: 10.1016/j.medmal.2004.03.006] [Reference Citation Analysis]
19 Jasmer RM, Snyder DC, Saukkonen JJ, Hopewell PC, Bernardo J, King MD, Kawamura LM, Daley CL; Short‐Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short‐Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Cost‐Effectiveness Analysis Based on a Multicenter Clinical Trial. CLIN INFECT DIS 2004;38:363-9. [DOI: 10.1086/380966] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
20 Floyd K. Costs and effectiveness--the impact of economic studies on TB control. Tuberculosis (Edinb) 2003;83:187-200. [PMID: 12758211 DOI: 10.1016/s1472-9792(02)00077-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
21 Jones T, Schaffner W. Miniature Chest Radiograph Screening for Tuberculosis in Jails: A Cost-effectiveness Analysis. Am J Respir Crit Care Med 2001;164:77-81. [DOI: 10.1164/ajrccm.164.1.2010108] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 1.7] [Reference Citation Analysis]
22 Mayaud C, Cadranel J. AIDS and the lung in a changing world. Thorax 2001;56:423-426. [DOI: 10.1136/thx.56.6.423] [Reference Citation Analysis]
23 Kaplan JE, Masur H, Holmes KK, Freedberg KA, Holtgrave D, Piscitelli SC, Van Dyke R, Watts H. An overview of the 1999 US Public Health Service/Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons. Clin Infect Dis 2000;30 Suppl 1:S15-28. [PMID: 10770912 DOI: 10.1086/313844] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
24 Verdejo Ortés J. [New criteria for the prophylaxis of infective diseases in patients infected by HIV]. Rev Clin Esp 2000;200:218-22. [PMID: 10857407 DOI: 10.1016/s0014-2565(00)70609-6] [Reference Citation Analysis]
25 Zumla A, Malon P, Henderson J, Grange JM. Impact of HIV infection on tuberculosis. Postgrad Med J 2000;76:259-68. [PMID: 10775277 DOI: 10.1136/pmj.76.895.259] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 3.5] [Reference Citation Analysis]
26 Telenti A, Iseman M. Drug-resistant tuberculosis: what do we do now? Drugs 2000;59:171-9. [PMID: 10730543 DOI: 10.2165/00003495-200059020-00002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 1.7] [Reference Citation Analysis]
27 Gbayisomore A, Lardizabal AA, Reichman LB. Update: prevention and treatment of tuberculosis. Curr Opin Infect Dis 2000;13:155-9. [PMID: 11964783 DOI: 10.1097/00001432-200004000-00010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
28 Lagrange P, Wargnier A, Herrmann J. Mycobacteriosis in the compromised host. Mem Inst Oswaldo Cruz 2000;95:163-70. [DOI: 10.1590/s0074-02762000000700027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]